By Sheeba M. | May 30, 2026
Trulieve Q1 Profit Inflection: EBITDA+ Territory After Five-Year Climb
Trulieve Cannabis (TRUL) reported Q1 2026 results last week—and for the first time in five years, the numbers showed what happens when a high-volume operator meets disciplined capital allocation. Adjusted EBITDA hit $78M, representing a 22% YoY increase despite modest revenue growth. For a company that burned cash as recently as 2021, this is the inflection moment every institutional investor has been waiting for.
The math is straightforward: 226 retail locations, $140M in quarterly revenue, and 40+ basis points of adjusted EBITDA margin improvement quarter-over-quarter. Management is guiding to $320M+ run-rate EBITDA by Q4—which, if executed, means Trulieve will be the first true “mega-cap” cannabis player with positive free cash flow and a clear path to dividend runway.
The Real Story: Unit Economics Durability
What separates Trulieve from peers isn’t just size—it’s repeatability. Each store generates ~$620K in monthly revenue with 28% incremental gross margins. That consistency gives management pricing power as cannabis commoditizes. When others are discounting to move volume, Trulieve’s scale lets it defend margin.
The federal rescheduling timeline remains uncertain, but TRUL‘s Q1 beat proves the MSO thesis works even without Schedule III status. Once banking access normalizes (and it will), expect institutional capital to flood the profitable operators. Trulieve’s cash position improves from here.
Consolidation Play: Who Gets Acquired?
As larger MSOs achieve profitability, acquisition targets become attractive. Smaller regional chains (think Verano Holdings, Ayr Wellness) with strong state footprints but weaker cash generation will be in acquisition conversations by Q3 2026. Trulieve has the dry powder to be consolidator-in-chief.
Forward Catalysts
- Q2 Earnings (July): Watch for $80M+ adjusted EBITDA guidance
- Federal Rescheduling Signal: Any timeline clarity triggers institutional reallocation
- Acquisition Announcement: Regional chain adds 40-60 stores and 15% YoY revenue
- NYSE Uplist Rumors: Profitability + scale = potential Nasdaq/NYSE listing by 2027
Bottom Line
The inflection is real. Trulieve‘s profitability milestone isn’t a one-quarter fluke—it’s validation of the high-volume, disciplined operator model. For portfolio managers watching cannabis from the sidelines, TRUL’s Q1 results are permission to get serious. Peers like Curaleaf and Verano have similar margin runway ahead, but Trulieve’s footprint and execution make it the surest bet on U.S. MSO consolidation and profitability.
Track TRUL and other cannabis stocks with the Weedstock Real-Time Tracker.
Sources
- SEC EDGAR – Trulieve Cannabis Q1 2026 10-Q Filing — Official earnings and financial statements
- Trulieve Investor Relations — Earnings press release and guidance
- Bloomberg Cannabis Terminal — Real-time TRUL trading and peer valuation multiples